Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Study Summary

This study is a first-in-human (FIH), Phase 1/1b, open-label, multicenter dose escalation and dose expansion study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JANX008 in adult subjects with advanced or metastatic carcinoma expressing EGFR.

Conditions

Non-Small Cell Lung Cancer Renal Cell Carcinoma Squamous Cell Carcinoma of the Head and Neck Colorectal Carcinoma Small Cell Lung Cancer Pancreatic Ductal Adenocarcinoma Triple-negative Breast Cancer

Interventions / Drugs

JANX008

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment130 participants

Primary Completion—

Lead SponsorJanux Therapeutics

Data Retrieved2026-04-11 04:18:24.248797+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.